Literature DB >> 26538074

Exercise as Therapy for Diabetic and Prediabetic Neuropathy.

J Robinson Singleton1, A Gordon Smith2, Robin L Marcus3.   

Abstract

Length-dependent neuropathy is the most common and costly complication of diabetes and frequently causes injury primarily to small-diameter cutaneous nociceptive fibers. Not only persistent hyperglycemia but also metabolic, endocrine, and inflammatory effects of obesity and dyslipidemia appear to play an important role in the development of diabetic neuropathy. Rational therapies aimed at direct control of glucose or its increased entry into the polyol pathway, oxidative or nitrosative stress, advanced glycation end product formation or signaling, microvascular ischemia, or adipocyte-derived toxicity have each failed in human trials of diabetic neuropathy. Aerobic exercise produces salutary effects in many of these pathogenic pathways simultaneously and, in both animal models and human trials, has been shown to improve symptoms of neuropathy and promote re-growth of cutaneous small-diameter fibers. Behavioral reduction in periods of seated, awake inactivity produces multimodal metabolic benefits similar to exercise, and the two strategies when combined may offer sustained benefit to peripheral nerve function.

Entities:  

Keywords:  Actigraphy; Diabetic neuropathy; Exercise; Human trials; Metabolic syndrome; Sedentary behavior

Mesh:

Year:  2015        PMID: 26538074     DOI: 10.1007/s11892-015-0682-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  98 in total

1.  Aerobic exercise alters analgesia and neurotrophin-3 synthesis in an animal model of chronic widespread pain.

Authors:  Neena K Sharma; Janelle M Ryals; Byron J Gajewski; Douglas E Wright
Journal:  Phys Ther       Date:  2010-03-25

2.  The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Authors:  Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

3.  A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.

Authors:  A J Krentz; L Honigsberger; S H Ellis; M Hardman; M Nattrass
Journal:  Diabet Med       Date:  1992-06       Impact factor: 4.359

4.  Fall and balance outcomes after an intervention to promote leg strength, balance, and walking in people with diabetic peripheral neuropathy: "feet first" randomized controlled trial.

Authors:  Robin L Kruse; Joseph W Lemaster; Richard W Madsen
Journal:  Phys Ther       Date:  2010-08-26

5.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

6.  Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats.

Authors:  Irina G Obrosova; Viktor R Drel; Christine L Oltman; Nazar Mashtalir; Jyoti Tibrewala; John T Groves; Mark A Yorek
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-10-02       Impact factor: 4.310

Review 7.  The metabolic syndrome and neuropathy: therapeutic challenges and opportunities.

Authors:  Brian Callaghan; Eva Feldman
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

8.  The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy.

Authors:  Michael Polydefkis; Peter Hauer; Soham Sheth; Michael Sirdofsky; John W Griffin; Justin C McArthur
Journal:  Brain       Date:  2004-05-05       Impact factor: 13.501

Review 9.  Biology and pathology of nonmyelinating Schwann cells.

Authors:  John W Griffin; Wesley J Thompson
Journal:  Glia       Date:  2008-11-01       Impact factor: 8.073

10.  Neurogenic factor-induced Langerhans cell activation in diabetic mice with mechanical allodynia.

Authors:  Jacqueline R Dauch; Diane E Bender; Lucía A Luna-Wong; Wilson Hsieh; Brandon M Yanik; Zachary A Kelly; Hsinlin T Cheng
Journal:  J Neuroinflammation       Date:  2013-05-14       Impact factor: 8.322

View more
  15 in total

1.  Weight Reduction as an Adjunctive Management Strategy for Diabetic Retinopathy.

Authors:  Rithwick Rajagopal
Journal:  Mo Med       Date:  2022 Jan-Feb

Review 2.  Obesity-Associated Neuropathy: Recent Preclinical Studies and Proposed Mechanisms.

Authors:  Raiza Bonomo; Sarah Kramer; Virginie M Aubert
Journal:  Antioxid Redox Signal       Date:  2022-05-23       Impact factor: 7.468

3.  Cardiac Autonomic Modulation in Response to Three Types of Exercise in Patients with Type 2 Diabetic Neuropathy.

Authors:  Elaheh Piralaiy; Marefat Siahkuhian; Saeed Dabbagh Nikookheslat; Linda S Pescatello; Mahboub Sheikhalizadeh; Mostafa Khani
Journal:  J Diabetes Metab Disord       Date:  2021-10-15

4.  Running on Trk to neuroprotection in diabetic retinopathy.

Authors:  Rithwick Rajagopal
Journal:  Eur J Neurosci       Date:  2018-05-15       Impact factor: 3.386

Review 5.  Physical Training and Activity in People With Diabetic Peripheral Neuropathy: Paradigm Shift.

Authors:  Patricia M Kluding; Sonja K Bareiss; Mary Hastings; Robin L Marcus; David R Sinacore; Michael J Mueller
Journal:  Phys Ther       Date:  2017-01-01

Review 6.  Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?

Authors:  Mark Yorek
Journal:  Curr Diabetes Rev       Date:  2022

7.  Effects of Exercise on Neuropathy in Streptozotocin-Induced Diabetic Rats.

Authors:  Eui Chang Lee; Myeong Ok Kim; Gill Ho Roh; Sang Eun Hong
Journal:  Ann Rehabil Med       Date:  2017-06-29

8.  Ethoxyquin is neuroprotective and partially prevents somatic and autonomic neuropathy in db/db mouse model of type 2 diabetes.

Authors:  Ying Liu; Yuan Sun; Osefame Ewaleifoh; Josh Wei; Ruifa Mi; Jing Zhu; Ahmet Hoke; Michael Polydefkis
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

Review 9.  Low-Dose Pulsatile Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy.

Authors:  April Ann Cox; Yves Sagot; Gael Hedou; Christina Grek; Travis Wilkes; Aaron I Vinik; Gautam Ghatnekar
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-02       Impact factor: 5.555

10.  Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome.

Authors:  Lucy M Hinder; Phillipe D O'Brien; John M Hayes; Carey Backus; Andrew P Solway; Catrina Sims-Robinson; Eva L Feldman
Journal:  Dis Model Mech       Date:  2017-04-05       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.